HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Eukaryotic Initiation Factor-4E

Subscribe to New Research on Eukaryotic Initiation Factor-4E

A peptide initiation factor that binds specifically to the 5' MRNA CAP STRUCTURE of MRNA in the CYTOPLASM. It is a component of the trimeric complex EIF4F.

Also Known As:

CDC33 Gene Product; EIF4E; Eukaryotic Peptide Initiation Factor-4E; EIF 4E; Eukaryotic Initiation Factor 4E; Eukaryotic Peptide Initiation Factor 4E; Factor-4E, Eukaryotic Initiation; Initiation Factor-4E, Eukaryotic; Peptide Initiation Factor EIF 4E; EIF-4E; Peptide Initiation Factor EIF-4E

Networked: 567 relevant articles (5 outcomes, 83 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 90489
  - Carrier Proteins: 11456
    - RNA-Binding Proteins: 969
      - RNA Cap-Binding Proteins: 43
        Eukaryotic Initiation Factor-4E: 567
        Drosophila 4EHP protein
        Drosophila eIF4E-1,2 protein
        S pombe eIF4E protein
  - Ribosomal Proteins: 662
    - Peptide Initiation Factors: 732
      - Eukaryotic Initiation Factors: 12
        Eukaryotic Initiation Factor-4F: 96
        Eukaryotic Initiation Factor-4E: 567
        Drosophila 4EHP protein
        Drosophila eIF4E-1,2 protein
        S pombe eIF4E protein

Experts

1.	Borden, Katherine L B: 23 articles (01/2015 - 03/2002)
2.	Sonenberg, Nahum: 19 articles (10/2015 - 04/2004)
3.	Pelletier, Jerry: 12 articles (09/2014 - 03/2004)
4.	Li, Benjamin D L: 12 articles (10/2009 - 05/2002)
5.	Topisirovic, Ivan: 11 articles (05/2015 - 09/2002)
6.	Kimball, Scot R: 10 articles (11/2015 - 09/2005)
7.	Bitterman, Peter B: 10 articles (07/2015 - 05/2004)
8.	Graff, Jeremy R: 10 articles (05/2013 - 01/2003)
9.	Meschonat, Carol: 9 articles (10/2009 - 01/2004)
10.	Fukunaga, Rikiro: 8 articles (06/2015 - 11/2007)

Related Diseases

1.	Neoplasms (Cancer) 01/30/2014 - "Together our findings provide the first preclinical proof-of-concept of novel Mnk degrading agents for Mnk/eIF4E based therapeutic treatment of breast cancers. " 03/18/2013 - "The results of this study further confirm over-expression of eIF4E in cervical cancer tumors and cell lines, and we have discovered that the transcription of eIF4E is induced by protein E6 of the human papillomavirus (HPV). " 03/18/2013 - "Several studies have reported that eIF4E is over-expressed in cervical cancer; however, the mechanism remains elusive. " 01/01/2011 - "Targeting the oncogene eIF4E in cancer: From the bench to clinical trials." 03/01/2009 - "Our studies show that HuR is upregulated in malignant cancer specimens characterized by high eIF4E levels and that its depletion leads to reduction in eIF4E levels. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2006 - "This study investigates the relationship between eIF4E and angiogenesis, as well as their prognostic impact in patients with human breast cancer. " 04/01/1998 - "The objective of this study is to determine if eIF4E oncoprotein overexpression is associated with eIF4E gene amplification in breast cancer using Western blots and competitive polymerase chain reaction (PCR). " 03/15/2015 - "Mechanistically, eIF4E silencing or blockade reduced the invasiveness and metastatic capability of breast cancer cells in a manner associated with decreased activity of matrix metalloproteinase (MMP)-3 and MMP-9. " 02/15/2015 - "Maintaining eIF4E levels below its proneoplastic threshold is an important anticancer defense in normal cells, with important implications for understanding pregnancy-associated breast cancer." 04/01/2014 - "Node-positive breast cancer patients were specifically studied to determine if eIF4E elevation increases risk for systemic dissemination. "
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/01/2013 - "The aim of this study was to detect the expression level of eIF4E gene in patients with non-treated, remission and non-remission/relapse acute myeloid leukemia (AML), and other non-malignant haematologic diseases so as to analyze and reveal the relationship of eIF4E gene expression with AML progression. " 05/02/2013 - "eIF4E is deregulated in acute myeloid leukemia (AML), and its aberrant activity contributes to leukemogenesis. " 04/01/2013 - "[Overexpression of eIF4E gene in acute myeloid leukemia and its relation with disease progression]." 01/01/2015 - "Finally, recent clinical work targeting eIF4E in acute myeloid leukemia patients with ribavirin is discussed. " 10/01/2013 - "The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia."
4.	Prostatic Neoplasms (Prostate Cancer) 02/20/2015 - "Our findings provide the first preclinical evidence that simultaneous inhibition of AR and eIF4E activation is a novel and efficacious therapeutic approach for PCa, and that NRs hold significant promise for treatment of advanced prostate cancer. " 04/01/2011 - "Re: eIF4E Phosphorylation Promotes Tumorigenesis and is Associated With Prostate Cancer Progression." 08/10/2010 - "Here, we show that knock-in mice expressing a nonphosphorylatable form of eIF4E are resistant to tumorigenesis in a prostate cancer model. " 08/10/2010 - "eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression." 01/01/2010 - "Moreover, the analysis suggested that direct targeting of the translational machinery, specifically eIF4E, could be efficacious in androgen-independent prostate cancers."
5.	Disease Progression 04/01/2013 - "It is concluded that the over-expression of eIF4E gene has been found in patients with AML, and its level obviously decreases along with remission of disease, thus the eIF4E gene may be a surveillance parameter for disease progression." 01/01/2015 - "Cox-regression analysis confirmed the ability of the p4EBP1/eIF4E signature to independently identify high-risk patients with a Hazard Ratio of 4.2 (CI = 2.1-8.6; P < 0.001), compared to 3.3 for tumour grade 3 and 4, and 2.3 for tumour stage 3 and 4. These data show the powerful prognostic value of the p4E-BP1/eIF4E signature for potential management of patients with clinically confined ccRCC, and in addition provides insights into the possible key synergistic determinants of disease progression and treatment response. " 01/01/2015 - "Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma." 04/01/2013 - "[Overexpression of eIF4E gene in acute myeloid leukemia and its relation with disease progression]." 03/15/2009 - "Elevated eIF4E activity is common in many human tumors and is associated with disease progression. "

Related Drugs and Biologics

1.	gemcitabine
2.	eIF-4B
3.	Peptide Initiation Factors (Initiation Factor)
4.	Eukaryotic Initiation Factor-4E
5.	Sirolimus (Rapamycin)
6.	Proteins (Proteins, Gene)
7.	Eukaryotic Initiation Factor-4G (Eukaryotic Initiation Factor 4G)
8.	Messenger RNA (mRNA)
9.	Eukaryotic Initiation Factor-4F (EIF4F)
10.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Chemoprevention
3.	Brachytherapy
4.	Drug Therapy (Chemotherapy)
5.	Therapeutics